Trevena (NASDAQ:TRVN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Trevena to post earnings of ($7.37) per share for the quarter.
Trevena Stock Down 1.6 %
Shares of TRVN stock opened at $1.20 on Friday. The company has a 50 day moving average of $1.54 and a 200-day moving average of $1.90. The firm has a market cap of $1.04 million, a P/E ratio of -0.03 and a beta of 1.05. Trevena has a 12-month low of $1.13 and a 12-month high of $11.25.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Trevena in a report on Friday. They issued a “sell” rating for the company.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- Stock Average Calculator
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Financial Services Stocks Investing
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- How to Evaluate a Stock Before Buying
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
